Testicular cancer follow-up costs in Germany from 2000 to 2015

Abstract

Purpose Advances in testicular cancer screening and therapy increased 10-year survival to 97% despite a rising incidence; eventually expanding the population of survivors requiring follow-up. We analyzed 10-year follow-up costs after testicular cancer treatment in Germany during 2000, 2008, and 2015. Methods Testicular cancer follow-up guidelines were extracted from the European Association of Urology. Per patient costs were estimated with a micro-costing approach considering direct and indirect medical expenses derived from expert interviews, literature research, and official scales of tariffs. Three perspectives covering costs for patients, providers, and insurers were included to estimate societal costs. Cost progression was compared across cancer histology, stage, stakeholders, resource use, and follow-up years. Results Mean 10-year follow-up costs per patient for stage I seminomatous germ-cell tumors (SGCT) on surveillance declined from EUR 11,995 in 2000 to EUR 4,430 in 2015 (p < 0.001). Advanced SGCT spending shrank from EUR 13,866 to EUR 9,724 (p < 0.001). In contrast, expenditure for stage II SGCT increased from EUR 7,159 to EUR 9,724 (p < 0.001). While insurers covered 32% of costs in 2000, only 13% of costs were reimbursed in 2015 (p < 0.001). 70% of SGCT follow-up resources were consumed by medical imaging (x-ray, CT, ultrasound, FDG-PET). Spending was unevenly distributed across follow-up years (years 1–2: 50%, years 3–5: 39%, years 5–10: 11%). Conclusions The increasing prevalence of testicular cancer survivors caused German statutory insurers to cut per patient cost by up to 80% by budgeting services and decreasing reimbursement rates. The economic burden was gradually redistributed to patients and providers.

Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma

“…An established costing methodology was employed to calculate the socio‐economic burden of RCC survivorship in Germany (Michaeli et al, 2021, 2022; Michaeli & Michaeli, 2022). In accordance with the EAU guidelines' risk‐stratification, we estimated costs across three distinct patient groups: low‐, medium‐, and high‐risk RCC.…”

Sonoelastography for Testicular Tumor Identification: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy

“…In China (Beijing), patients spent US$1577.7 and US$100.7 on 18 inpatient and 143 outpatient visits, respectively [8]. In Germany, the follow-up expenses after Stage I seminomatous germ cell tumors per patient totaled EUR 4430 in 2015 [9]. Although the survival rate was high [10], survivors experienced long-term mental health issues, such as depression, anxiety, and distress [11][12][13][14].…”